Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc.

NASDAQ:APLS

Overview | Financials
Company Name Apellis Pharmaceuticals, Inc.
Symbol APLS
Currency USD
Price 18.82
Market Cap 2,365,335,240
Dividend Yield 0%
52-week-range 16.1 - 43.76
Industry Biotechnology
Sector Healthcare
CEO Dr. Cedric Francois M.D., Ph.D.
Website https://www.apellis.com

An error occurred while fetching data.

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA)

Related Stocks

The Ensign Group, Inc. logo

The Ensign Group, Inc.

ENSG

150.63 USD

Medpace Holdings, Inc. logo

Medpace Holdings, Inc.

MEDP

306.07 USD

Tandem Diabetes Care, Inc. logo

Tandem Diabetes Care, Inc.

TNDM

20.63 USD

Lantheus Holdings, Inc. logo

Lantheus Holdings, Inc.

LNTH

77.69 USD

ICU Medical, Inc. logo

ICU Medical, Inc.

ICUI

130.54 USD

Premier, Inc. logo

Premier, Inc.

PINC

23.06 USD

QuidelOrtho Corporation logo

QuidelOrtho Corporation

QDEL

30.29 USD

Alkermes plc logo

Alkermes plc

ALKS

31.27 USD

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

CRSP

38.04 USD

Financials

Numbers are in millions USD

Numbers are in millions USD